QIAGEN TherascreenKRASRGQ Assay, QIAGENKRASPyro Assay, and Dideoxy Sequencing for Clinical Laboratory Analysis ofKRASMutations in Tumor Specimens

Alqahtani, Qamra M.; Crowley, Ann M.; Rapp, Sharleen A.; Cushman‐Vokoun, Allison M.

doi:10.1093/labmed/lmv009

Cited by 3 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is interesting to note that not all CDx play the role of identifying patients that would benefit from a given therapy, as in the case of the FDA-approved CDx QIAGEN Therascreen 141 . This RT-qPCR type diagnostic is used to eliminate patients from receiving the drugs Vectibix and Erbitux for metastatic colorectal cancer.…”

Section: Developing a Ppm Therapymentioning

confidence: 99%

The growing role of precision and personalized medicine for cancer treatment

et al. 2018

View full text Add to dashboard Cite

Cancer is a devastating disease that takes the lives of hundreds of thousands of people every year. Due to disease heterogeneity, standard treatments, such as chemotherapy or radiation, are effective in only a subset of the patient population. Tumors can have different underlying genetic causes and may express different proteins in one patient versus another. This inherent variability of cancer lends itself to the growing field of precision and personalized medicine (PPM). There are many ongoing efforts to acquire PPM data in order to characterize molecular differences between tumors. Some PPM products are already available to link these differences to an effective drug. It is clear that PPM cancer treatments can result in immense patient benefits, and companies and regulatory agencies have begun to recognize this. However, broader changes to the healthcare and insurance systems must be addressed if PPM is to become part of standard cancer care.

show abstract

Section: Developing a Ppm Therapymentioning

confidence: 99%

The growing role of precision and personalized medicine for cancer treatment

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The details of the eligibility criteria have been previously reported [17]. RAS mutation was examined in paraffin-embedded tumor tissues at individual institutions using validated methods approved by the Japanese Ministry of Labor and Welfare [18,19]. In Japan, RAS mutation analysis was performed at only KRAS exon 2 (codons 12 and 13) until Apr 2015, and expanded to KRAS/NRAS exons 2, 3, and 4…”

Section: Patientsmentioning

confidence: 99%

Phase II study of S-1 on alternate days plus bevacizumab in patients aged ≥ 75 years with metastatic colorectal cancer (J-SAVER)

et al. 2019

View full text Add to dashboard Cite

Background Alternate-day administration of S-1 is thought to reduce toxicities. This phase II study evaluated S-1 on alternate days combined with bevacizumab as first-line treatment for elderly patients with metastatic colorectal cancer. Patients and Methods Eligible patients had histologically proven colorectal adenocarcinoma, measurable metastatic lesions, age ≥75 years, Eastern Cooperative Oncology Group performance status ≤1, no previous chemotherapy, and refused oxaliplatin-or irinotecan-containing regimens. Patients received 40 mg, 50 mg, or 60 mg (body surface area ≤1.25 m 2 , >1.25 to ≤1.50 m 2 , or >1.50 m 2 , respectively) of S-1 twice orally on Sunday, Monday, Wednesday, and Friday every week. Bevacizumab (7.5 mg/kg) was administered every 3 weeks. The primary endpoint was progression-free survival. Results Of 54 enrolled patients, 50 patients were evaluated for efficacy and 53 for safety. The median age was 79 years (range, 75-88 years). The median progression-free survival was 8.1 months (95% confidence interval, 6.7-9.5 months). The median overall survival was 23.1 months (95% confidence interval, 17.4-28.8 months). The response rate was 44% (95% confidence interval, 30.2-57.8%), and the disease control rate was 88% (95% confidence interval, 79.0-97.0%). Grade 3 or higher hematologic, non-hematologic, and bevacizumab-related adverse events occurred in 9%, 11%, and 25% of patients, 4 respectively. The most common grade 3 and 4 treatment-related adverse events were hypertension (11%), nausea (6%), fatigue (6%), anemia (6%), and proteinuria (6%). Only 6 patients discontinued treatment due to adverse events. Conclusion S-1 on alternate days combined with bevacizumab showed better tolerability and comparable survival compared with the results of similar studies.

show abstract